APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

This phase II trial studies the effect of APL-2 when given in combination with either pembrolizumab or pembrolizumab and bevacizumab compared with bevacizumab alone in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent) and a buildup of fluid and cancer cells (malignant effusion). APL-2 may limit tumor progression, decrease malignant effusion production, and improve the immune system's response against cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and ma

Trial Details

NCT ID
NCT04919629
Phase
PHASE2
Sponsor
Roswell Park Cancer Institute
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Bevacizumab
  • Biopsy
  • Biospecimen Collection
  • Pegcetacoplan
  • Pembrolizumab
  • Questionnaire Administration
Locations (sample)
  • Buffalo, New York, United States|42.88645,-78.87837

Key Eligibility Criteria

  • Age \>= 18 years of age on day of signing informed consent
  • Recurrent epithelial ovarian/fallopian tube or primary peritoneal cancer (serous, clear cell, endometrioid, mixed or poorly differentiated or carci…
  • Symptomatic ascites or pleural effusion or both requiring \>= 1 drainage within 4-weeks of study entry or has a peritoneal/pleural drainage cathete…
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →